Dermata TherapeuticsDRMA
13F holders, Q1 2026 (March 31)7holders
4new positions
4sold out
$1.21avg. 13F price*
At the end of Q1 2026, 7 institutions reported holding Dermata Therapeutics Inc. (DRMA) in their 13F filings, unchanged from Q4 2025. 4 opened new positions and 4 sold out. The largest holders were Geode Capital Management, LLC ($58K), UBS Group AG ($43K) and Welch & Forbes LLC ($24K).
- Company
- Dermata Therapeutics Inc.
- CUSIP
- 249845504
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $85K |
| Exits | 4 | $55K |
All 13F filers, Q4 2025 → Q1 2026: 104,438 shares bought and 24,838 shares sold, net +79,600 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Geode Capital Management, LLC | 0.00% | New | 48,334 | $58K |
| UBS Group AG | 0.00% | Add +2778.6% | 35,608 | $43K |
| Welch & Forbes LLC | 0.00% | New | 20,000 | $24K |
| MCF Advisors LLC | 0.00% | New | 1,732 | $2K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -64.2% | 716 | $866 |
| SBI Securities Co., Ltd. | 0.00% | No change | 101 | $122 |
| Citigroup Inc. | 0.00% | New | 1 | $1 |
"% of holder's portfolio" is DRMA's weight in each manager's 13F, not the share of Dermata Therapeutics Inc. the manager owns.